Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 2/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713557 | 0.83 | GABRR1 (0.42) | GGT1GABRR1LMNAFOLH1RIMKLA | |
| SCHEMBL10977790 | 0.82 | NOD1 (0.49) | GGT1ACENOD1 | |
| SCHEMBL6010257 | 0.80 | GABRR1 (0.39) | GGT1GABRR1LMNA | |
| SCHEMBL2993459 | 0.79 | ECE1 (0.37) | GGT1GABRR1LMNA | |
| SCHEMBL3379281 | 0.78 | GABRR1 (0.40) | GGT1GABRR1LMNAFOLH1RIMKLA | |
| SCHEMBL3378525 | 0.78 | GABRR1 (0.40) | GGT1GABRR1LMNAFOLH1RIMKLA | |
| SCHEMBL31419895 | 0.78 | GABRR1 (0.40) | GGT1GABRR1LMNAFOLH1RIMKLA | |
| SCHEMBL5974504 | 0.76 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 | |
| SCHEMBL468724 | 0.76 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 | |
| SCHEMBL5974497 | 0.76 | SMN1; SMN2 (0.50) | GABRR1LMNAFOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | GGT1 1685/4885GABRR1 2416/4885LMNA 2783/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | GGT1 1180/4885GABRR1 4051/4885LMNA 1070/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | GGT1 811/4885GABRR1 1973/4885LMNA 1866/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | GGT1 2237/4885GABRR1 4232/4885LMNA 1388/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | GGT1 929/4885GABRR1 3761/4885LMNA 1701/4885 |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | GGT1 652/4885GABRR1 719/4885LMNA 2077/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | GGT1 2410/4885GABRR1 3887/4885LMNA 636/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | GGT1 887/4885GABRR1 1370/4885LMNA 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.